- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Interventions
- Semaglutide, Zenagamtide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
Condition Directory
Diabetes clinical trials
Directory of U.S. ClinicalTrials.gov public records for Diabetes. Browse Diabetes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 23, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8332
Shown on this page
12
Current sort
Recently updated
Condition scope
Diabetes
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Diabetes studies are organized in the registry
Generic “diabetes” listings mix type 1, type 2, and gestational diabetes, so the subtype is the first thing to pin down — this directory also has a dedicated type 2 diabetes page. Device studies (continuous glucose monitors, insulin delivery systems) are a large slice of the portfolio and are easiest to find by querying the device term itself.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 85–96 of 8,332 matching trials for Diabetes.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
- Interventions
- Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY948862), Others except finerenone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238,038 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Breast Cancer, Diabetes, Colon Cancer, Cardiovascular Disease
- Interventions
- Family Health History
- Behavioral
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gestational Diabetes, Pregnancy, High Risk, Overweight and Obesity
- Interventions
- Intensive glycemic targets, Standard glycemic targets
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Norman, Oklahoma + 2 more
- Conditions
- Type 2 Diabetes, Obesity & Overweight
- Interventions
- Nex Playground Activity Program
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prediabetes
- Interventions
- FUERTE Arm, Standard care, No Intervention
- Behavioral · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dietary Habits
- Interventions
- Day shift protocol - Diet order A-B, Day shift protocol - Diet order B-A, Night shift protocol - Diet order A-B, Night shift protocol - Diet order B-A
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Weight Gain, Overweight, Insulin Resistance, Obesity, Diabetes Mellitus, Type 2
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1983
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Type 2 Diabetes
- Interventions
- Orforglipron, Dapagliflozin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 962 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 19
- States / cities
- Canoga Park, California • Long Beach, California • Los Alamitos, California + 16 more
- Conditions
- Eye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration, Traumatic Optic Neuropathy, Optic Atrophy
- Interventions
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Biological
- Lead sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Naples, Florida
- Conditions
- Diabetic Retinopathy
- Interventions
- Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 37
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 34 more
About this Diabetes clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Diabetes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Diabetes.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Diabetes.